Are Living Kidney Donors At Risk For Hypertension?
NSMC intern Manish Lalwani explains it graphically
The Balance of Giving: Understanding Risks for Living Kidney Donors
Estudio RADAR - El Resumen Visual
El Resumen Visual
¿Realmente existen diferencias entre los pacientes con enfermedades renales raras de otras causas de ERC?
Veamos este resumen visual creado por el miembro de la facultad NephEdC, Brian Rifkin, el cual activa el RaDaR hacia las enfermedades renales raras.
The RADAR study - Visual Abstract
Are patients with rare kidney diseases different from other CKD? Check out the beautiful VAs by NSMC faculty Brian Rifkin and Cristina Popa
Mapping the course of rare renal diseases with RaDaR
Post hoc del estudio COMPASS _ El Resumen Visual
El Resumen Visual
¿Cuál es el riesgo de desarrollar enfermedad renal con el uso de inhibidores de la bomba de protones?
Observemos este resumen visual creado por la pasante de NephEdC, Rowan Zyada, del análisis post-hoc en el estudio COMPASS el cual trata de reflejar el riesgo asociado entre el uso de IBP y la incidencia de enfermedad renal.
COMPASS Trial post hoc analysis - The Visual Abstract
Are proton pump inhibitors detrimental to kidney function?
Checkout the visual abstract for the post hoc observational analysis from the COMPASS Trial by NSMC Intern Rowan Zyada!
Heart-burn and Kidney Churn
FLOW Trial: Are Innovative Treatments Accessible to the Patient Communities in Need?`
FLOW - El Resumen Visual
¡La Marea de Semaglutida llegó a la Enfermedad Renal Crónica!
Del monstruo de Gila al estudio FLOW.
Para ello, veamos el hermoso resumen visual realizado por la pasante de NephEdC, Anjana Gopal, traducido por Milagros Flores.
FLOW- the Visual Abstract
‘FLOW’ing with the Semaglu’TIDE’!
Check the beautiful visual abstract made by NephEdC intern Anjana Gopal, with an appearance of the Gila monster as well.
FLOWing with the SemagluTIDE
The KDIGO 2024 CKD Guidelines: part 2
KDIGO 2024 CKD guidelines part 2 - Visual Abstract
Checkout the top 10 takeaways by KDIGO on the management of people with CKD. VA by Dr Vamsidhar Veeranki
The KDIGO CKD 2024 Guidelines Part 1: Evaluation and Risk Stratification
KDIGO CKD GUIDELINES - VISUAL ABSTRACT
Check out the TOP 10 takeaways from KDIGO - CKD guidelines on evaluation of people with or at risk of CKD by NSMC Intern Stephanie Torres
Apolipoprotein E in Dense Deposit Disease and C3 GN - Visual Abstract
Shedding Light on the Dense Matter of C3 Glomerulopathy
Healing, Hype, or Harm: The NefIgArd trial
The NeflgArd Part B Visual Abstract
Does targeted-release formulation of Budesonide improve kidney function in primary IgA Nephropathy? Check out the VA by NSMC Intern Anant Pilawan on NefIgArd part B trial